单核细胞来源白细胞介素-1β驱动S100A12诱导人冠状动脉内皮细胞无菌性炎症激活:对川崎病发病机制的启示
该研究探讨S100A12在川崎病(KD)发病机制中的作用。结果显示,KD患者血清S100A12水平与可溶性血管细胞黏附分子1滴度相关;人冠状动脉内皮细胞(HCAECs)对直接S100A12刺激无反应,但对S100A12刺激的单核细胞上清液有反应,且该反应严格依赖白细胞介素-1β(IL-1β)信号(P < 0.001)。结论提示S100A12以IL-1β依赖方式激活HCAECs,为IL-1靶向治疗KD提供机制支持。
要点
- KD患者血清S100A12水平与sVCAM-1滴度相关(rs = -0.6,P = 0.0003)。
- HCAECs对直接S100A12刺激无反应,但对S100A12刺激的单核细胞上清液有反应。
- 该反应严格依赖IL-1β信号(P < 0.001),支持IL-1靶向治疗KD。
核心结论
- S100A12作为KD中高表达的无菌性炎症介质,以IL-1β依赖方式激活人冠状动脉内皮细胞。
- 数据为S100A12和IL-1β参与KD发病机制提供新见解,并支持当前IL-1靶向治疗KD的研究。
研究设计与样本
- 分析30例KD患者静脉注射免疫球蛋白(IVIG)治疗前后不同阶段的血清样本中S100A12、细胞因子、趋化因子及内皮细胞活化可溶性标志物表达。
- 以原代人冠状动脉内皮细胞(HCAECs)分析其对直接S100A12或脂多糖(LPS)刺激的反应性,采用实时定量逆转录聚合酶链反应检测细胞因子和内皮细胞黏附分子mRNA表达。
- 将HCAECs培养于经LPS或S100A12刺激的原代人单核细胞条件培养基中,并观察IVIG或细胞因子拮抗剂的影响。
主要发现
- KD患者治疗前S100A12水平与IVIG治疗过程中可溶性血管细胞黏附分子1滴度相关(rs = -0.6,P = 0.0003)。
- HCAECs虽表达RAGE和TLR-4受体,但对直接S100A12刺激无反应。
- HCAECs对S100A12刺激的单核细胞上清液有反应,表现为炎症细胞因子和黏附分子基因表达。
- 该反应严格依赖白细胞介素-1β(IL-1β)信号(P < 0.001)。
临床怎么用
- S100A12可能作为KD无菌性炎症介质,通过单核细胞来源IL-1β间接激活冠状动脉内皮细胞。
- 研究结果支持IL-1靶向治疗用于KD患者的临床研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Kawasaki disease (KD) is an acute vasculitis of childhood, predominantly affecting the coronary arteries. S100A12, a granulocyte-derived agonist of both the receptor for advanced glycation end products (RAGE) and Toll-like receptor 4 (TLR-4), is strongly up-regulated in KD. This study was undertaken to investigate the potential contributions of S100A12 to the pathogenesis of KD. METHODS: Serum samples from patients with KD (n = 30) at different stages pre- and post-intravenous immunoglobulin (IVIG) treatment were analyzed for the expression of S100A12, cytokines, chemokines, and soluble markers of endothelial cell activation. Primary human coronary artery endothelial cells (HCAECs) were analyzed for responsiveness to direct stimulation with S100A12 or lipopolysaccharide (LPS), as assessed by real-time quantitative reverse transcription-polymerase chain reaction analysis of cytokine and endothelial cell adhesion molecule messenger RNA expression. Alternatively, HCAECs were cultured in conditioned medium obtained from primary human monocytes that were stimulated with LPS or S100A12 in the absence or presence of IVIG or cytokine antagonists. RESULTS: In the serum of patients with KD, pretreatment S100A12 levels were associated with soluble vascular cell adhesion molecule 1 titers in the course of IVIG therapy (rs = -0.6, P = 0.0003). Yet, HCAECs were not responsive to direct S100A12 stimulation, despite the presence of appropriate receptors (RAGE, TLR-4). HCAECs did, however, respond to supernatants obtained from S100A12-stimulated primary human monocytes, as evidenced by the gene expression of inflammatory cytokines and adhesion molecules. This response was strictly dependent on interleukin-1β (IL-1β) signaling (P < 0.001). CONCLUSION: In its role as a highly expressed mediator of sterile inflammation in KD, S100A12 appears to activate HCAECs in an IL-1β-dependent manner. These data provide new mechanistic insights into the contributions of S100A12 and IL-1β to disease pathogenesis, and may therefore support current IL-1-targeting studies in the treatment of patients with KD.
引用
- Armaroli G, Verweyen E, Pretzer C, et al. Monocyte-Derived Interleukin-1β As the Driver of S100A12-Induced Sterile Inflammatory Activation of Human Coronary Artery Endothelial Cells: Implications for the Pathogenesis of Kawasaki Disease. Arthritis Rheumatol. 2019. PMID: 30447136. doi:10.1002/art.40784
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。